Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

Stock Information for Stellus Capital Investment Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Stellus Capital Investment Corporation

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
Arcturus Therapeutics to Attend Upcoming Investor Conferences
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
Arcturus Therapeutics to Attend Upcoming Investor Conferences
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.